Research - Treatt feature image - 03072019 - JPG



Market CapCHF134m

Last Close CHF0.14

Evolva is a Swiss biotech company focused on the research, development and commercialisation of products based on nature. The company has leading businesses in Flavours and Fragrances, Health Ingredients and Health Protection.

More Evolva content >

Investment summary

Evolva’s overall geographical and product footprint continues to expand and the pipeline remains robust. The company’s aim remains to reach cash break-even by FY23. Evolva has transformed itself from an R&D-driven enterprise towards a commercial company with a product-based revenue model. It witnessed growth across all segments during H121 and now expects to see positive gross profits from Q421.

Y/E Dec
Revenue (CHFm)
P/E (x)
P/CF (x)
2019A 11.6 (12.3) (15.6) (2.0) N/A N/A
2020A 7.5 (16.7) (23.4) (2.9) N/A N/A
2021E 14.2 (17.3) (18.6) (2.1) N/A N/A
2022E 27.5 (2.5) (3.8) (0.4) N/A N/A
Industry outlook

Food and health ingredients continue to be in the sweet spot as consumers demand healthier products with cleaner labels without compromising on taste or convenience. Evolva’s fermentation platform aims to deliver these benefits while reducing production costs.

Last updated on 14/10/2021
Content on Evolva
Evolva – EKF interview
Consumer | Edison TV | 13 October 2021
Evolva – Progressing towards break-even
Consumer | Update | 3 September 2021
Evolva – Addressing the bottlenecks
Consumer | Update | 3 March 2021
View more
Register to receive research on Evolva as it is published
Share price graph
Balance sheet
Forecast net debt (CHFm) 4.5
Forecast gearing ratio (%) 4
Price performance
Actual (8.0) (22.1) (38.5)
Relative* (6.4) (21.1) (46.8)
52-week high/low CHF0.3/CHF0.1
*% relative to local index
Key management
Beat In-Albon Chairman
Oliver Walker CEO